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S U M M A R Y
Objectives: The aim of this study was to assess the characteristics of periprosthetic joint infection (PJI)
due to Staphylococcus lugdunensis and to compare these to the characteristics of PJI due to Staphylococcus
aureus and Staphylococcus epidermidis.
Methods: A retrospective multicentre study including all consecutive cases of S. lugdunensis PJI (2000–
2014) was performed. Eighty-eight cases of staphylococcal PJI were recorded: 28 due to S. lugdunensis,
30 to S. aureus, and 30 to S. epidermidis, as identiﬁed by Vitek 2 or API Staph (bioMe´rieux).
Results: Clinical symptoms were more often reported in the S. lugdunensis group, and the median delay
between surgery and infection was shorter for the S. lugdunensis group than for the S. aureus and S.
epidermidis groups. Regarding antibiotic susceptibility, the S. lugdunensis strains were susceptible to
antibiotics and 61% of the patients could be treated with levoﬂoxacin + rifampicin. The outcome of the PJI
was favourable for 89% of patients with S. lugdunensis, 83% with S. aureus, and 97% with S. epidermidis.
Conclusion: S. lugdunensis is an emerging pathogen with a pathogenicity quite similar to that of S.
aureus. This coagulase-negative Staphylococcus must be identiﬁed precisely in PJI, in order to select the
appropriate surgical treatment and antibiotics .
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Periprosthetic joint infections (PJI) are the main complication of
knee and hip prosthetic arthroplasty. Between 1% and 3% of
patients undergoing prosthesis implantation are affected by these
infections.1,2 Staphylococci (Staphylococcus aureus and coagulase-
negative staphylococci (CoNS)) are the major pathogens involved
in PJI.2,3 Staphylococcus lugdunensis is a CoNS that is considered
part of the normal ﬂora of human skin, as are other CoNS species.4
It is widely distributed across the skin, especially in the inguinal
and perineal areas.5 S. lugdunensis was ﬁrst described in 1988 and
was shown to have morphological, biochemical, and pathogenic
properties close to those of S. aureus.6 These common properties
can lead to misidentiﬁcation of S. lugdunensis: it may be positive for
clumping factor and thus could show positive latex agglutination* Corresponding author. Tel.: +33 623018433.
E-mail address: julielourtet@hotmail.com (J. Lourtet-Hascoe¨t).
http://dx.doi.org/10.1016/j.ijid.2016.08.007
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International S
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).test results, like S. aureus. S. lugdunensis is also ornithine
decarboxylase-positive, like other CoNS, and may therefore be
mistaken for another CoNS. Recent developments in bacteriologi-
cal techniques have led to considerable improvements in species
identiﬁcation. Automated systems and mass spectrometry have
resolved the misidentiﬁcation problems especially for CoNS.
The virulence factors of S. lugdunensis are shared with S. aureus,
such as the ability to adhere to host proteins (ﬁbronectin,
ﬁbrinogen), slime production, and the secretion of various toxins.7
Moreover, the gene agr (accessory regulator), ica operon, fbl, atlL,
vwbl, and slush factors involved in bacterial virulence have been
identiﬁed in S. lugdunensis strains. All of these common properties
show that S. lugdunensis is an aggressive pathogen and may be
responsible for serious infections.8,9 S. lugdunensis is also described
as a bacterium capable of bioﬁlm production due to AtlL autolysin,
particularly in prosthetic device-associated infections.10
The pathogenic role of S. lugdunensis was emphasized in
1991 when a total of 155 S. lugdunensis specimens were isolated
from different sites in 143 patients.4 In that study, the patientsociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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abscesses. S. lugdunensis is well described as an aggressive
pathogen involved in brain, thoracic, cutaneous, and soft tissue
abscesses.11–13 Furthermore, S. lugdunensis can cause endocarditis
on native valves, septicaemia, deep tissue infections, and
peritonitis.4,9 However, few studies have reported S. lugdunensis
bone and joint infections.
S. lugdunensis shares several properties with S. aureus: in
particular, S. lugdunensis may produce bound coagulase via a
clumping factor. However, unlike S. aureus, it does not produce free
coagulase. The rapid agglutination test (short coagulase test) may
be positive for S. lugdunensis because of the same surface proteins
shared with S. aureus. For these reasons it can be misidentiﬁed, and
this could affect the management of PJI treatment. S. lugdunensis is
more virulent and the clinical manifestations are more similar to S.
aureus than CoNS.
Since its ﬁrst description in 1988 by Freney et al.,6,11 S.
lugdunensis has been acknowledged as an agent causing severe
infections such as endocarditis,14,15 soft tissue infections, perito-
nitis, breast and cerebral abscesses, vascular graft infections,
septicemia,4,12,13 and toxic shock syndrome.16 It appears that
fewer than 30 cases of PJI due to S. lugdunensis have been reported
in the literature.
The objective of this study was to assess the differences
between S. lugdunensis and two other Staphylococcus species – S.
aureus and S. epidermidis – in terms of clinical symptoms, delay
between surgery and infection, antibiotic susceptibility, and
clinical outcomes of PJI.
2. Materials and methods
2.1. Study population
A retrospective and descriptive study was conducted from
2000 to 2014, including patients from three orthopaedic centres in
the same area. Eighty-eight consecutive cases of monomicrobialTable 1
Patient characteristics and clinical information for cases of Staphylococcus lugdunensis 
Patient Sex Age (years) Medical history P
1 F 49 None K
2 M 79 CVD K
3 F 75 None H
4 M 87 CVD K
5 F 63 None F
6 F 68 None S
7 M 63 None H
8 F 67 CVD H
9 M 37 None K
10 M 55 CVD K
11 F 83 None H
12 M 40 None K
13 F 70 None K
14 M 70 None K
15 M 40 None H
16 F 82 Diabetes mellitus H
17 M 48 Rheumatoid disease H
18 F 78 None K
19 F 66 Cancer K
20 M 64 Cancer H
21 M 66 None K
22 M 41 None H
23 F 87 None K
24 F 71 None K
25 F 61 None K
26 F 78 None K
27 F 84 None K
28 M 71 None H
F, female; M, male; CVD, cardiovascular disease; D, dehiscence; SLI, signs of local inﬂastaphylococcal PJI due to S. lugdunensis (n = 28), S. aureus (n = 30),
and S. epidermidis (n = 30) were analyzed.
2.2. Patients and samples
Data and information collected included age, sex, medical
history, localization of the infection, clinical signs, surgical type,
antibiotic therapy, duration of treatment, outcome post treatment,
and delay between surgery and bacterial identiﬁcation. These data
are summarized in Table 1.
All patients included in the study were suffering from a PJI. The
diagnosis was based on multidisciplinary criteria and was assessed
clinically, biologically, microbiologically, histopathologically, and
radiologically.17
The diagnosis of PJI was established in the presence of one
major criterion or two minor criteria: (1) the major criteria were at
least two positive periprosthetic cultures with phenotypically
identical organisms, or a sinus tract communicating with the joint;
(2) minor criteria were a C-reactive protein (CRP) value >10 mg/l
and a histological analysis of periprosthetic tissue conﬁrming a
septic process .18
The surgical technique was chosen by the orthopaedic surgeon
in consultation with an infectious diseases specialist.17 Irrigation
and debridement was the technique used for early PJI with less
than 1 month between prosthesis implantation and clinical
symptoms of infection. One-stage surgery was considered for
patients with a chronic PJI but with an adequate state of bone and
tissues. A gentamicin bone cement (Palacos-Genta; Zimmer
1800 West Center Street Warsaw, Poland) was used whenever
possible. A two-stage revision procedure was indicated for patients
who were not candidates for irrigation and debridement or one-
stage surgery. These patients presented a chronic PJI, with bone
and soft tissue defects. This strategy was used for patients who
could undergo at least two surgeries. A local spacer impregnated
with gentamicin was used until the placement of a new prosthesis.
Patient outcomes were based on at least 1 year of follow-up.
This consisted of a multidisciplinary consultation (with a surgeonperiprosthetic joint infection
rosthesis site Clinical signs Surgery type
nee Pain Irrigation and debridement
nee Pain Irrigation and debridement
ip Pain Irrigation and debridement
nee Fever, pain, SLI One-stage surgery
oot Fever, pain, ﬁstula Irrigation and debridement
houlder Fever, pain, SLI Irrigation and debridement
ip Pain Two-stage revision
ip Pain Two-stage revision
nee Fever, pain One-stage surgery
nee Fever, pain Irrigation and debridement
ip Fever, pain, SLI Irrigation and debridement
nee Fever, pain, SLI Irrigation and debridement
nee Fever, SLI, pain Two-stage revision
nee Fever, pain, SLI Two-stage revision
ip Fever, pain, SLI Irrigation and debridement
ip Fever, D, pain Irrigation and debridement
ip SLI Irrigation and debridement
nee Fistula Two-stage revision
nee Loosening Two-stage revision
ip Loosening Two-stage revision
nee SLI, fever, pain One-stage surgery
ip SLI, pain Two-stage revision
nee Fistula Two-stage revision
nee SLI, fever, pain Two-stage revision
nee Fever, D, SLI One-stage surgery
nee D One-stage surgery
nee D Two-stage revision
ip Fever, D, SLI One-stage surgery
mmation.
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radiological evaluation and a blood analysis for CRP. A favourable
outcome was considered a good clinical recovery, satisfactory joint
mobility, and no signs of inﬂammation.
Intraoperative bone tissue, synovial membranes, and articular
ﬂuid samples were obtained for the microbiological diagnosis. It
was recommended that antibiotics be stopped 15 days prior to
surgery in order to obtain growing bacteria in culture.
At least three intraoperative deep samples were collected per
patient. After collection, the samples were transferred to the
microbiology laboratory within less than 1 h.
2.3. Bacteriological culture
For each suspected site, hard and soft tissue specimens were
collected in sterile glass vials. Articular ﬂuid was inoculated into
blood culture bottles. All samples were incubated under aerobic
conditions with CO2 and an anaerobic atmosphere for 15 days.
Gram staining was performed for each sample on day 1.
Hard and soft tissue specimens were crushed and vortexed in
1 ml of saline solution for 10 min. Standard cultures were performed
on Columbia blood agar, PolyViteX chocolate agar, and thioglycolate
solution (Oxoid, Dardilly, France). Articular ﬂuids were inoculated
into blood culture bottles and onto solid agar media.
Media were observed daily for microbial growth. Bacteriologi-
cal criteria for a positive diagnosis of infection were the following:
at least one positive sample for S. aureus-positive cultures; at least
two positive samples for S. epidermidis- and S. lugdunensis-positive
cultures.
Only monomicrobial cultures with S. aureus, S. lugdunensis, and
S. epidermidis were selected. Seven polymicrobial infections
including S. lugdunensis were excluded. In these cases, the PJI
involved bacteria of the cutaneous ﬂora: CoNS, corynebacteria, or
Propionibacterium acnes. The exclusion of polymicrobial infections
was necessary to be certain of the bacterium that caused the PJI
. Thus all clinical, biological, and treatment-related results were
speciﬁcally connected to a single bacterial species: S. aureus, S.
lugdunensis, or S. epidermidis.
In the case of a positive culture, identiﬁcation was performed by
automated technique (Vitek 2; bioMe´rieux, Marcy l’Etoile, France)
or manual technique (API Staph; bioMe´rieux). When identiﬁcation
results were conﬂicting, complementary tests were performed to
conﬁrm the species identiﬁcation: (1) S. aureus: positive latexTable 2
Comparison of populations with Staphylococcus lugdunensis, Staphylococcus aureus, and
S. lugdunensis
(n = 28)
Age (years) 67.5 (58–78) 
Number of males 13 (46.4%) 
Prosthesis site
Knee 16 (57%) 
Hip 10 (36%) 
Other 2 (7%) 
Clinical signs
Fever 15 (53.6%) 
Local signs of inﬂammation 13 (46.4%) 
Surgery type
Irrigation and debridement 11 (39.3%) 
One-stage surgery 6 (21.4%) 
Two-stage revision 11 (39.3%) 
Delay from surgery to infection (weeks) 12 (3–56) 
Samples
Number of positive samples 3.5 (1.5–5) 
Total number of samples 5 (2–6) 
Treatment duration (weeks) 7 
Outcome positive 89% 
a Data are displayed as the median (interquartile range), or as the number (percentagglutination; (2) S. lugdunensis: typical salty smell, positive
pyrrolidonyl arylamidase (L-PYR) test; (3) S. epidermidis: colistin
resistance detected by disk diffusion test.
Antimicrobial susceptibilities were tested by Vitek 2 (bioMe´r-
ieux) according to the recommendations of the Committee on
Antibiotic Susceptibility of the French Society of Microbiology.19
Methicillin resistance was interpreted from the oxacillin minimum
inhibitory concentration (MIC). Staphylococcus strains were
considered susceptible when the MIC was between 0.5 and
2 mg/ml. Conﬂicting results for methicillin susceptibility were
veriﬁed by cefoxitin disk (Bio-Rad, Marnes-la-Coquette, France).
2.4. Statistical analysis
Continuous variables are presented as the median and
interquartile range, while categorical variables are presented as
the count and proportion. For the univariate analysis, continuous
data were compared among the three groups of patients according
to the type of Staphylococcus by Kruskal–Wallis test. Qualitative
variables were compared by Chi-square test (or Fisher’s exact test
when necessary). The statistical analysis was performed using
Stata 11.2 software (StataCorp, College Station, TX, USA).
3. Results
3.1. Population study
Twenty-eight cases of S. lugdunensis PJI were recorded between
2000 and 2014 at the three orthopaedic centres in the same area.
Clinical and surgical data for these S. lugdunensis PJI are detailed in
Table 1.
Age, sex, prosthesis site, clinical and biological signs, and the
types of surgery performed in the three groups are summarized in
Table 2.
The populations of the three groups were comparable statisti-
cally for age (p = 0.34) and sex (p = 0.196).
With regard to S. lugdunensis patients, eight (29%) presented a
comorbidity: four (14%) had cardiovascular disease, one (4%) had
inﬂammatory rheumatism, one (4%) had diabetes mellitus, and
two (7%) had a history of cancer. The median CRP value in this
group was 42 mg/l.
Nine (30%) of the S. aureus patients had a comorbidity: ﬁve
(17%) had cardiovascular disease, one (3%) had been treated for Staphylococcus epidermidis periprosthetic joint infectionsa
S. aureus
(n = 30)
S. epidermidis
(n = 30)
p-Value
60.5 (44–75) 67 (61–77) 0.34
20 (66.7%) 20 (66.7%) 0.196
18 (60%) 11 (36.7%) 0.145
9 (30%) 16 (53%) 0.158
3 (10%) 3 (10%)
9 (30%) 4 (13.3%) 0.004
7 (23.3%) 4 (13.3%) 0.015
10 (33.3%) 5 (16.7%) 0.144
12 (40%) 16 (53.3%) 0.044
8 (26.7%) 9 (30%) 0.568
44 (12–144) 84 (44–192) 0.0449
4 (3–5) 4 (3–5) 0.449
4 (3–5) 5 (4–6) 0.413
7 7
83% 97% 0.233
age).
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diabetes mellitus, and one (3%) had hepatitis C. Thirteen (43%) of
the S. epidermidis patients presented a comorbidity: ﬁve (17%) had
cardiovascular disease, one (3%) had been treated for cancer, and
ﬁve (17%) had diabetes mellitus. CRP data were available for only a
few of the patients with S. aureus and S. epidermidis PJIs and so are
not presented.
3.2. Surgical intervention
The median delay between surgery and infection and the type
of surgery performed in the three groups are presented in
Table 2. For S. lugdunensis PJI, the median delay was statistically
shorter than in the other groups (p = 0.0449).
3.3. Bacteriological results
Bacteriological results for the deep intraoperative samples in the
three groups are presented in Table 2; no signiﬁcant difference was
found between the three groups regarding the number of positive
samples (p = 0.449) or the total number of samples (p = 0.413).
S. lugdunensis culture results and antibiotic resistance proﬁles
are detailed in Table 3. A comparison of antibiotic resistance isTable 4
Comparison of antibiotic resistance and treatment in the three groups
Staphylococcus aureus Staphylococcus
Resistance to
Penicillin G 22 (73.3%) 30(100%) 
Methicillin 4 (13.3%) 23 (76.7%) 
FQ 5 (16.7%) 18 (60%) 
RIF 1 (3.3%) 6 (20%) 
Clindamycin 8 (26.7%) 19 (63.3%) 
Treatment with
FQ + RIF 25 (83.3%) 12 (40%) 
Linezolid 2 (6.7%) 12 (40%) 
FQ, ﬂuoroquinolones; RIF, rifampicin.
Table 3
Microbiological results and patient treatments and outcomes for cases of Staphylococcu
Patient Antibiotic resistance Treatment 
1 Penicillin, fosfomycin Fluoroquinolone, rifa
2 Penicillin Fluoroquinolone, rifa
3 Penicillin Fluoroquinolone, rifa
4 Penicillin, rifampicin Fluoroquinolone, clin
5 Penicillin, MLS Fluoroquinolone, rifa
6 None SXT, rifampicin 
7 Penicillin, fosfomycin Linezolid 
8 Penicillin Linezolid 
9 None Fluoroquinolone, rifa
10 Penicillin Fluoroquinolone, rifa
11 None Fluoroquinolone, rifa
12 Penicillin Fluoroquinolone, clin
13 None Fluoroquinolone, rifa
14 Penicillin Fluoroquinolone, rifa
15 None Fluoroquinolone, rifa
16 Penicillin, MLS, ﬂuoroquinolone, tetracycline Fluoroquinolone, rifa
17 Fosfomycin, MLS Fluoroquinolone, rifa
18 Fosfomycin Oxacillin 
19 Fosfomycin Oxacillin, FA 
20 Fosfomycin Oxacillin 
21 None AMC, rifampicin 
22 Fosfomycin Fluoroquinolone, rifa
23 Fosfomycin, ﬂuoroquinolone Clindamycin 
24 Penicillin Fluoroquinolone, clin
25 None Fluoroquinolone, rifa
26 Penicillin, AF Fluoroquinolone, rifa
27 None Fluoroquinolone, rifa
28 Penicillin, fosfomycin Fluoroquinolone, rifa
SXT, trimethoprim–sulfamethoxazole; AMC, amoxicillin+clavulanic acid; FA=AF, fusidicpresented in Table 4. S. lugdunensis was signiﬁcantly the most
susceptible species regarding penicillin G, methicillin, ﬂuoroqui-
nolones, clindamycin (p = 0.000), and rifampicin (0.038). Antibiotic
resistance proﬁles in the three groups are compared in Figure 1.
3.4. Medical therapy
All patients received an empiric intravenous antibiotic regimen
with vancomycin or daptomycin following surgery. After approxi-
mately 1 week of parenteral antibiotics, oral relay therapy was
implemented for a mean duration of 7 weeks in all three groups.
The main oral medical treatments are presented in
Table 4. Antibiotics prescribed in S. lugdunensis and S. aureus PJI
were mostly ﬂuoroquinolones associated with rifampicin. Because
S. epidermidis strains were more resistant than S. aureus and S.
lugdunensis, second-line antibiotics like linezolid were more often
used. A comparison of the oral medical treatment in the three
groups is shown in Figure 2.
3.5. Patient outcomes
The outcome was evaluated during a follow-up period starting
at the end of treatment and continuing for at least 12 months for all epidermidis Staphylococcus lugdunensis p-Value
14 (50%) 0.000
0 0.000
1 (6.6%) 0.000
1 (3.6%) 0.038
3 (10.7%) 0.000
17 (60.7%) 0.003
2 (7.1%) 0.001
s lugdunensis periprosthetic joint infection
Duration (weeks) Positive/total samples Outcome
mpicin 6 2/5 Favourable
mpicin 6 5/5 Favourable
mpicin 6 2/2 Favourable
damycin 6 4/4 Favourable
mpicin 6 1/1 Favourable
6 4/5 Favourable
3 2/6 Favourable
4 6/7 Favourable
mpicin 6 2/2 Favourable
mpicin 6 3/6 Favourable
mpicin 6 2/2 Favourable
damycin 8 2/2 Favourable
mpicin 6 5/5 Unfavourable
mpicin 9 5/5 Favourable
mpicin 8 5/5 Favourable
mpicin 10 5/5 Unfavourable
mpicin 6 6/7 Favourable
17 3/4 Favourable
65 3/5 Favourable
4 4/5 Favourable
17 1/1 Favourable
mpicin 16 2/2 Favourable
13 4/5 Favourable
damycin 16 2/2 Favourable
mpicin 6 9/9 Favourable
mpicin 6 6/6 Favourable
mpicin 8 6/6 Unfavourable
mpicin 8 2/7 Favourable
 acid; MLS, macrolide-lincosamide-streptogramin B; None, no antibiotic resistance.
Figure 1. Antibiotic resistance of Staphylococcus lugdunensis, Staphylococcus aureus, and Staphylococcus epidermidis strains.
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statistically comparable in the three groups (p = 0.233).
Nine unfavourable outcomes were reported in the total
population. The overall success rate of the surgical technique
applied, as deﬁned by a lack of relapse, was 85% for irrigation and
debridement, 97% for one-stage surgery, and 86% for two-stage
revision.
4. Discussion
This study compared the clinical and bacteriological character-
istics of 28 consecutive cases of S. lugdunensis PJI to those in PJI
caused by other staphylococci.
S. lugdunensis colonization is described on the skin, especially in
the inguinal and perineal areas.5 This localization may play a role in
the potential haematogenous or subcutaneous dissemination,
which could lead to bone and joint infections. Several studies on S.
lugdunensis bone and joint infections have reported osteomyeli-
tis,4,22 septic arthritis,23 and PJI.4,24 They have all described the
invasive nature of these S. lugdunensis infections.Figure 2. Antibiotic treatment of Staphylococcus lugdunensis, StaphylococcusIn this study, signiﬁcantly more clinical symptoms such as pain,
fever, and signs of local inﬂammation were observed in the S.
lugdunensis and S. aureus series than in the S. epidermidis series. CRP
at the time of diagnosis was not reported for all patients (especially
for those with S. epidermidis PJI). Measurements were available for
half of the patients with S. lugdunensis PJI and the mean value was
42 mg/l, which is much higher than the value usually reported for
S. epidermidis PJI.25
The delay between surgery and infection was signiﬁcantly
shorter in S. lugdunensis and S. aureus PJI compared to S. epidermidis
PJI. Others studies have also reported a short delay in S. lugdunensis
PJI. This result conﬁrms the similar clinical course of S. lugdunensis
PJI and S. aureus infections.23,26
With regard to the type of surgical intervention, irrigation and
debridement and two-stage revision were performed for S.
lugdunensis and S. aureus PJI. In all other published studies, the
most frequent type of surgery selected was two-stage revision
with placement of an antibiotic spacer.24,26,27 The treatment
success rate for S. lugdunensis PJI was overall the same whatever
the type of surgery. Three patients had an unfavourable outcome: aureus, and Staphylococcus epidermidis periprosthetic joint infections.
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revision.
In this study, S. lugdunensis was responsible for knee PJI more
than hip PJI, as was S. aureus. In contrast, S. epidermidis was more
involved in hip PJI. These data may conﬁrm the suggestion of Shah
et al., that S. lugdunensis could preferentially infect knees.26
Although S. lugdunensis shares many properties with S. aureus,
one of the main differences between the two species is the
antimicrobial susceptibility. It was found that S. lugdunensis strains
were all susceptible to methicillin, and half were resistant to
penicillin G. These results are different to those of some previous
studies, especially for penicillin G resistance.4,11,26 They seem to
indicate that the parenteral b-lactam adopted to treat an S.
lugdunensis PJI should be an anti-staphylococcal b-lactam agent.
As in previous studies, a high rate of susceptibility (90–100%) to
quinolones, rifampicin, and clindamycin was found.22,23,26,27 No
strain was resistant to linezolid or trimethoprim–sulfamethoxa-
zole (SXT). S. aureus strains were quite susceptible to methicillin
(87%), but it was found that 17% of strains were resistant to
quinolones and 27% to clindamycin. In comparison, 77% of S.
epidermidis strains were resistant to methicillin, 60% to quinolones,
and 20% to rifampicin, the ﬁrst-line antibiotics for the treatment of
PJI. Thus S. aureus and S. lugdunensis strains in this study were
much more susceptible than S. epidermidis strains, as reported in
other publications on staphylococcal bone and joint infections.28
The treatment of S. lugdunensis PJI was a combination of
ﬂuoroquinolone + rifampicin for 61% of the patients. This is the
reference treatment for methicillin-susceptible CoNS PJI recom-
mended in French and international guidelines.17,29 This combi-
nation was also chosen as the ﬁrst-line treatment for S. aureus PJI,
but only for 40% of patients with an S. epidermidis PJI. More second-
line antibiotics, such as linezolid, SXT, cyclins, clindamycin, and
fusidic acid, were used for the treatment of S. epidermidis PJI, due to
the resistance of S. epidermidis.
The duration of treatment was on average 7 weeks in the three
groups. It appears that the good outcomes achieved in these
patients were more a result of early surgery (at <1 month)
associated with an adapted antibiotic combination than the
duration of treatment. Previous studies have reported a mean
duration of treatment of 4 to 8 weeks.22–24
Moreover 97% of patients with an S. epidermidis PJI had a
favourable outcome, compared to 89% of patients with an S.
lugdunensis PJI and 83% of patients with an S. aureus PJI (p = 0.233).
These results were not signiﬁcant in this population, but they
nevertheless suggest the high pathogenicity of S. lugdunensis.
The total number of S. lugdunensis PJI cases collected in this
study was only 28; this may not be statistically sufﬁcient to
conﬁrm all of the observations. The present results warrant
conﬁrmation in prospective studies conducted on a larger number
of S. lugdunensis PJI samples.
To conclude, S. lugdunensis is classiﬁed as a CoNS, but the clinical
features of S. lugdunensis PJI, the early aspect of the infection, and
the relapses observed are similar to those in S. aureus PJI. Regarding
the microbiological diagnosis, the species of CoNS in PJI must be
identiﬁed precisely and treatment adapted to the antibiotic
susceptibility, even if only one deep sample is positive in culture.
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